Article content

Unsecured, non-interest-bearing loan provides additional working capital support

Article content

WINNIPEG, Manitoba, Oct. 16, 2026 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”), a biotechnology company commercializing and developing technologies and products that address microbial biofilms, today announced that it has accepted an unsecured loan in the principal amount of $250,000 (the “Loan”) from Philip Renaud, Chair of the Company’s Board of Directors and an approved control person of the Company.

Article content

Article content

Article content

The Loan does not bear interest and is repayable on demand. No bonus was paid or is payable by the Company in connection with the Loan. The Company intends to use the proceeds for general working capital and corporate purposes and intends to repay the Loan from future capital raises or general revenue.

Article content

Article content

The Loan constitutes a “related party transaction” under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”) and TSX Venture Exchange Policy 5.9. The Company is relying on the exemptions from the formal valuation and minority shareholder approval requirements in sections 5.5(a) and 5.7(1)(a) of MI 61-101 because the fair market value of the Loan does not exceed 25% of the Company’s market capitalization.

Article content

“This unsecured loan provides Kane Biotech with additional working capital as we continue to advance our corporate and commercial priorities,” said Philip Renaud, Chair of Kane Biotech’s Board of Directors. “I remain committed to supporting the Company as management pursues its strategy and longer-term financing alternatives”.

Article content

Article content

About Kane Biotech Inc. (TSX-V:KNE)

Article content

Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray and revyve Antimicrobial Skin and Wound Cleanser are all U.S. FDA 510(k) cleared. revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray are also Health Canada approved. To learn more, visit revyvegel.com or revyvegel.ca.

Article content

Join Kane’s Distribution List & Social Media:

Article content

To stay informed on the latest developments, sign up for the Company’s email distribution list here.

Article content

Follow Kane

Article content

Article content

Article content

Article content

For more information:

Article content

Dr. Robert Huizinga                          Ray Dupuis
Interim CEO                                        Chief Financial Officer          
Kane Biotech Inc.                               Kane Biotech Inc.
[email protected]              [email protected]
(780) 970-1100                                   (204) 298-2200